Clinical trials: sponsored by Research Inc
Major Depressive Disorder
Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium
The objective of this study is to evaluate the safety, tolerability, and preliminary efficacy of the Motif eXternally powered Cortical Stimulation (XCS) System when used as indicated for treatment-resistant depression (TRD).
- Trial name
- RESONATE (NCT07594483)
- Testing
- Motif XCS System
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Motif Neurotech, Inc.
Glioblastoma
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed…
- Trial name
- GBM AGILE (NCT03970447)
- Testing
- Temozolomide, Lomustine, Regorafenib
- Where
- 63 sites in United States, Australia and 4 more
- Volunteers
- 2,250 people
- Sponsor
- Global Coalition for Adaptive Research
Surgical Wound Infection, Traumatic Wound Infection
A Study of Amicidin-β Topical Solution for Patients With a Contaminated or Infected Surgical or Traumatic Wound or Cutaneous Abscess
The goal of this Phase 1 clinical trial is to learn about the safety profile of Amicidin-β topical solution applied directly into contaminated or infected surgical or traumatic wounds or cutaneous abscess during a surgical…
- Conditions
- Surgical Wound Infection, Traumatic Wound Infection, Cutaneous Abscess
- Trial name
- NCT07379684
- Testing
- Amicidin-β topical solution - 15 mL, Amicidin-β topical solution - 50 mL, Standard of Care (SOC)
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- Macro Biologics, Inc.
Advanced Solid Tumor
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
The purpose of this first-in-human study is to identify a recommend dose(s) for subsequent larger studies (recommended dose(s) for expansion, RDE), examining increasing doses of M0324, primarily looking at safety, but also…
- Trial name
- TITER (NCT07166601)
- Testing
- M0324, Pembrolizumab, mFOLFIRINOX
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 77 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Lumbar Disc Herniation
Intradiscal Ozone/Oxygen Injection for Treatment of Contained Lumbar Disc Herniation
This study is retrospectively designed and aims to evaluate and summarize safety and performance data in eligible participants who have undergone Intradiscal ozone-oxygen injection for treatment of lumbar disc herniation with the…
- Trial name
- NCT07910422
- Testing
- Intradiscal ozone-oxygene injection
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- Beam Research, Inc.
Longevity, Preventive Medicine
Tirzepatide and Organ-specific Biological Aging
The purpose of this study is to evaluate blood-based measures of organ-specific biological age, with a particular focus on the brain, and to investigate their relationship with established clinical indicators of health and their…
- Conditions
- Longevity, Preventive Medicine, Biological Ageing
- Trial name
- NCT07906041
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Atria Research and Global Health Institute (ARGHI)
Advanced Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma
Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers
Subjects will receive zolbetuximab with either CAPOX every 3 weeks or mFOLFOX6 every 2 weeks. The chemotherapy regimen chosen, mFOLFOX6 or CAPOX is per the treating investigator discretion and subject preference.
- Trial name
- NCT07723534
- Testing
- Zolbetuximab, mFOLFOX6, CAPOX
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Midhun Malla
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer and HR+/HER2- Metastatic Breast Cancer
This phase II trial studies the side effects and best dose of ivermectin in combination with balstilimab or pembrolizumab and to see how well they they work in shrinking tumors in patients with triple negative breast cancer and…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, HR+ / HER2- Advanced Breast Cancer
- Trial name
- NCT05318469
- Testing
- Ivermectin, Balstilmab, Pembrolizumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Yuan Yuan
Leukemia, Myeloid, Acute
A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
The purpose of this study is to determine the efficacy of cusatuzumab in combination with azacitidine in participants with previously untreated acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy.
- Trial name
- CULMINATE (NCT04023526)
- Testing
- Azacitidine, Cusatuzumab
- Where
- 56 sites in Australia, Brazil and 7 more
- Volunteers
- 103 people
- Sponsor
- OncoVerity, Inc.
Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
The purpose of this study is to determine whether the combination of a neoantigen vaccine targeting the DNAJB1-PRKACA fusion kinase in combination with DRP-104, Nivolumab and Ipilimumab is safe and yields a clinically compelling…
- Trial name
- NCT07430202
- Testing
- DNAJB1-PRKACA Peptide Vaccine, DRP-104, Nivolumab
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Intractable Pain, Palliative Care
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
This study will examine the safety of giving the experimental drug, resiniferatoxin (RTX), to treat severe pain in patients with advanced cancer. RTX is a chemical extracted from a cactus-like plant.
- Trial name
- NCT00804154
- Testing
- Intrathecal Resiniferatoxin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Parkinson's Disease (PD), Deep Brain Stimulation
A Study of Buntanetap in Participants With PD
This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts.
- Trial name
- NCT07284784
- Testing
- buntanetap/posiphen
- Where
- 29 sites in United States
- Volunteers
- 500 people
- Sponsor
- Annovis Bio Inc.
Refractory Glaucoma
PAUL® Glaucoma Implant Safety and Effectiveness Study
This prospective, multicenter clinical study is designed to evaluate the safety and effectiveness of the PAUL® Glaucoma Implant in adult patients with refractory glaucoma.
- Trial name
- NCT07907055
- Testing
- PAUL® Glaucoma Implant
- Volunteers
- 65 people
- Sponsor
- Clinical Research Consultants, Inc.
Prostate Cancer Metastatic, Prostate Cancer
Exercise in Prostate Cancer
The goal of this clinical trial is to learn how exercise intervention affects circulating tumor cells (CTC) in men with advanced prostate cancer.
- Trial name
- NCT06165302
- Testing
- Exercise Intervention
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Aortic Valve Regurgitation, Aortic Valve Disease Mixed
J-Valve Transfemoral Pivotal Study
The primary objective of this study is to assess the safety and efficacy of the J-Valve Transfemoral (TF) System in patients with symptomatic, severe (grade 3 or 4), native aortic valve regurgitation (AR) and AR-dominant mixed…
- Trial name
- JOURNEY (NCT06455787)
- Testing
- J-Valve Transfemoral (TF) System
- Where
- 42 sites in United States, Canada and 3 more
- Volunteers
- 194 people
- Sponsor
- JC Medical, Inc., an affiliate of Edwards Lifesciences LLC
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
This phase I/II study tests how well zimberelimab and quemliclustat work in combination with chemotherapy (mFOLFIRINOX) in treating patients pancreatic adenocarcinoma that may or may not be able to be removed by surgery…
- Trial name
- NCT05688215
- Testing
- Biospecimen Collection, Computed Tomography, Core Biopsy
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Asperger's Disorder, Asperger Disorder
QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)
BRIEF SUMMARY A. "What is the purpose of this study?" BACKGROUND. The QAIAx clinical trial (Quantum SI/SGI Public Health Agency), known operationally as the "AI City Hall Project," represents a landmark intergovernmental research…
- Conditions
- Asperger's Disorder, Asperger Disorder, Autism Disorder, Autism
- Trial name
- QAIAx (NCT07661823)
- Testing
- AI City Hall Project (AIhealth4u - Public Health Central), AI City Hall Project (QAIAx Microcity A - AI Public Health Central)
- Where
- United States
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Veterans Recovery Network Inc.
Cancer
Met Non Small Cell Cancer Registry (MOMENT)
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC)…
- Trial name
- NCT05376891
- Where
- 80 sites in United States, Austria and 12 more
- Volunteers
- 700 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Migraine
Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy
The purpose of the study is to evaluate the risk of pregnancy and infant outcomes among women with migraine exposed to rimegepant during pregnancy and in two rimegepant unexposed comparator groups.
- Trial name
- NCT05198245
- Testing
- Rimegepant, Various, No intervention
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Human Papillomavirus (HPV), HPV Associated Cancers
C2001P-CS3: Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIV
The overall goal of this study is to inform the design and establish feasibility for a future clinical trial to determine the optimal management of women living with HIV (WLWH) with high-risk human papillomavirus (hrHPV) detected…
- Conditions
- Human Papillomavirus (HPV), HPV Associated Cancers, Cervical Cancer, Human Immunodeficiency Virus (HIV)
- Trial name
- NCT07576842
- Testing
- HPV DNA Testing (Abbott Alinity m HPV Assay), Visual Inspection with Acetic Acid, Cervical Histology (Biopsy Procedures)
- Where
- Botswana
- Volunteers
- 750 people
- Sponsor
- University of California, San Diego